このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Mega Lifesciences マネジメント

マネジメント基準チェック /24

Mega Lifesciences'の CEO はVivek Dhawanで、 Jan1988年に任命され、の在任期間は 36.42年です。は、会社の株式の6.62%を直接所有しており、その価値はTHB 2.21B 。経営陣と取締役会の平均在任期間はそれぞれ26.4年と11.3年です。

主要情報

Vivek Dhawan

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	36.4yrs
CEOの所有権	6.6%
経営陣の平均在職期間	26.4yrs
取締役会の平均在任期間	11.3yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Vivek Dhawan (63 yo)

36.4yrs

在職期間

Mr. Vivek Dhawan has been the Chief Executive Officer of Mega Lifesciences Public Company Limited since 1988 and has been its Chief Coach since 2013. Mr. Dhawan started with Medicap and built Lupin Laborat...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Vivek Dhawan	CEO, Chief Coach & Executive Director	36.4yrs	データなし	6.62% THB 2.2b
Thomas Abraham	CFO & Executive Director	26.4yrs	データなし	0.76% THB 255.1m
Deepak Panjwani	Chief Risk & Compliance Officer	no data	データなし	データなし
Paramjit Sawhney	President of International	no data	データなし	1.5% THB 500.5m
Girish Wadhwa	President of Myanmar	no data	データなし	データなし
Manoj Gurbuxani	Deputy Chief Financial Officer	4.4yrs	データなし	0.000010% THB 3.3k
Duangnapa Tongsiri	President of Mega We Care Thailand	no data	データなし	1.48% THB 492.8m
Sujintana Boonworapat	Corporate Secretary	no data	データなし	0.021% THB 6.9m

26.4yrs

平均在職期間

57.5yo

平均年齢

経験豊富な経営陣: MEGAの経営陣は経験豊富で経験豊富です（平均在職期間は26.4年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Vivek Dhawan	CEO, Chief Coach & Executive Director	11.4yrs	データなし	6.62% THB 2.2b
Thomas Abraham	CFO & Executive Director	26.4yrs	データなし	0.76% THB 255.1m
Yim Chi	Independent Vice Chairma	11.3yrs	฿1.58m	データなし
Kirit Chimanlal Shah	Non-Executive Director	11.3yrs	฿661.50k	50.13% THB 16.7b
Shiraz Poonevala	Non-Executive Director	11.3yrs	฿661.50k	データなし
Ishaan Shah	Non-Executive Director	11.3yrs	฿661.50k	データなし
Mechai Viravaidya	Independent Chairman	11.3yrs	฿2.21m	データなし
Sameera Shah	Non-Executive Director	11.3yrs	฿661.50k	データなし
Thor Santhisiri	Independent Director	11.3yrs	฿1.15m	0.013% THB 4.2m
Vijay Karwal	Independent Director	3.1yrs	฿1.15m	データなし
Nithinart Sinthudeacha	Independent Director	1.4yrs	฿1.15m	データなし

11.3yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: MEGAの取締役会は経験豊富で経験豊富です ( 11.3年の平均在任期間)。

Mega Lifesciences マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Less than half of directors are independent

Less than half of directors are independent

Mega Lifesciences Public Company Limited Appoints Alan Kam to Be the Vice Chairman of the Board of Directors

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2022

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2021

Recent updates

First quarter 2024 earnings released: EPS: ฿0.55 (vs ฿0.52 in 1Q 2023)

Upcoming dividend of ฿0.80 per share

Final dividend reduced to ฿0.80

Mega Lifesciences Public Company Limited Proposes Dividend for the Year Ended December 31, 2023, Payable on April 22, 2024

Full year 2023 earnings released: EPS: ฿2.29 (vs ฿2.57 in FY 2022)

Now 20% undervalued

Mega Lifesciences Public Company Limited to Report Q3, 2024 Results on Nov 12, 2024

Third quarter 2023 earnings: EPS misses analyst expectations

Now 21% undervalued

Now 21% undervalued

Upcoming dividend of ฿0.80 per share at 3.8% yield

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2023to June 30, 2023, Payable on September 8, 2023

Now 20% undervalued after recent price drop

Mega Lifesciences Public Company Limited to Report Q2, 2023 Results on Aug 11, 2023

Now 25% undervalued after recent price drop

First quarter 2023 earnings: EPS misses analyst expectations

Now 22% undervalued after recent price drop

Upcoming dividend of ฿0.85 per share at 3.5% yield

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Now 21% undervalued after recent price drop

Upcoming dividend of ฿0.75 per share

Second quarter 2022 earnings: Revenues exceed analyst expectations

Mega Lifesciences Public Company Limited Announces Cash Dividend for the Period from January 1, 2022 to June 30, 2022, Payable on September 9, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Mega Lifesciences Public Company Limited Appoints Alan Kam to Be the Vice Chairman of the Board of Directors

Upcoming dividend of ฿0.86 per share

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2022

Mega Lifesciences Public Company Limited Proposes Dividend for Year Ended December 31, 2021, Payable on April 22, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 21% undervalued

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS ฿0.70 (vs ฿0.39 in 3Q 2020)

Investor sentiment improved over the past week

Upcoming dividend of ฿0.52 per share

Second quarter 2021 earnings released: EPS ฿0.58 (vs ฿0.35 in 2Q 2020)

First quarter 2021 earnings released: EPS ฿0.38 (vs ฿0.37 in 1Q 2020)

New 90-day low: ฿35.50

Mega Lifesciences Public Company Limited, Annual General Meeting, Apr 05, 2021

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS ฿1.60 (vs ฿1.31 in FY 2019)

New 90-day high: ฿40.50

New 90-day high: ฿39.00

Third quarter 2020 earnings released: EPS ฿0.39

Revenue and earnings beat expectations

New 90-day low: ฿32.00

New 90-day low: ฿33.00

Mega Lifesciences Public Company Limited (SET:MEGA) completed the acquisition of 83.33% stake in PT Futamed Pharmaceuticals from PT Ersons and others for approximately IDR 180 billion.

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24